OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024
OPKO Health, Inc. (OPK) is set to announce its operating and financial results for the three and 12 months ending December 31, 2023. The company's senior management will provide a business update and discuss financial guidance during a conference call on February 27, 2024.
02/22/2024 - 04:05 PM
MIAMI, Feb. 22, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on Tuesday, February 27, 2024. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on February 27th beginning at 4:30 p.m. Eastern time.
CONFERENCE CALL & WEBCAST INFORMATION
OPKO encourages participants to pre-register for the conference call using this link . Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants may register at any time, including up to and after the call start time. Those unable to pre-register may participate by dialing 833-630-0584 (U.S.) or 412-317-1815 (International). A webcast of the call can also be accessed at OPKO’s Investor Relations page and here .
A telephone replay will be available until March 5, 2024 by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) and providing the passcode 6034226. A webcast replay will be available beginning approximately one hour after the completion of the live conference call here .
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com .
Contacts:
LHA Investor Relations ybriggs@lhai.com bvoss@lhai.com
When will OPKO Health, Inc. report its operating and financial results for the three and 12 months ended December 31, 2023?
OPKO Health, Inc. (OPK) plans to report its operating and financial results on February 27, 2024, after the close of the U.S. financial markets.
What time will the conference call and live audio webcast begin on February 27, 2024?
The conference call and live audio webcast will begin at 4:30 p.m. Eastern time on February 27, 2024.
How can participants pre-register for the conference call?
Participants can pre-register for the conference call using the provided link to receive a unique PIN for immediate access to the call.
What are the dial-in numbers for participants unable to pre-register?
Participants who are unable to pre-register can dial 833-630-0584 (U.S.) or 412-317-1815 (International) to join the conference call.
How long will the telephone replay be available?
The telephone replay will be available until March 5, 2024, by dialing 877-344-7529 (U.S.) or 412-317-0088 (International) with the passcode 6034226.
Opko Health Inc
NASDAQ:OPK
OPK Rankings
#4112 Ranked by Stock Gains
OPK Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Miami
About OPK
opko health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. our diagnostics business includes bioreference laboratories, the nation's third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4kscore® prostate cancer test and the claros® 1 in office immunoassay platform. our pharmaceutical business features rayaldee, an fda approved treatment for shpt in stage 3-4 ckd patients with vitamin d insufficiency (launched in november 2016), varubitm for chemotherapy induced nausea and vomiting (oral formulation launched by partner tesaro and iv formulation pending fda approval), opk88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in phase 2 clinical trials, among the new class of glp-1 glucagon receptor dual agonists, and opk88003, a selective androgen receptor modulator for benig
